moa glp 1 agonist Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics GLP1 Receptor Agonists—Effects beyond Obesity
Description
vTv Therapeutics Inc
Regulatory re-positioning of obesity as a cardiometabolic disease, payer re-classification of GLP-1 receptor agonists as essential therapies after positive cardiovascular-outcome trials, and rapid employer adoption of coverage are converging to accelerate prescription volumes
Specifically, prolonged GLP-1RA administration (13 years or longer) has been associated with elevated thyroid cancer risk in certain populations [4], while high concentrations of liraglutide (100 nM) have been demonstrated to promote breast cancer progression via the NOX4/ROS/VEGF signaling pathway [18]
One medication of growing interest to our patients is Ozempic, which contains the active ingredient semaglutide
Insulin and IGF-1 signaling GLP-1 medications improve insulin sensitivity, which is one of their major metabolic benefits
Belli M, Barone L, Bellia A, et al
